Get the Stockscreener App
8.77
0.00%
0.00
After Hours:
8.77
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Cross Above 50-Day Moving AverageTime to Sell? - MarketBeat
KalVista Pharmaceuticals receives Orphan Drug Designation and Submits New Drug Application for Sebetralstat in Japan for Hereditary Angioedema | Events & NewsInvesting in JapanJapan External Trade Organization - jetro.go.jp
Trend Tracker for (KALV) - Stock Traders Daily
Equities Analysts Issue Forecasts for KALV FY2026 Earnings - MarketBeat
Hennion & Walsh Asset Management Inc. Makes New $634,000 Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Japan grants orphan drug status to HAE treatment By Investing.com - Investing.com Canada
Japan grants orphan drug status to HAE treatment - Investing.com
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema - Business Wire
Hennion & Walsh Asset Management Inc. Makes New Investment in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista wins new Buy at BofA on potential of lead candidate - MSN
Barclays PLC Boosts Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
Barclays PLC Purchases 54,257 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
KalVista Pharmaceuticals Awards Strategic Employee Stock Options Worth 111,000 Shares - StockTitan
TD Cowen Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
TD Cowen backs Kalvista stock as peak sales potential for sebetralstat exceeds $750MM - Investing.com Canada
KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at TD Cowen - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Holdings Raised by Geode Capital Management LLC - Defense World
Barclays PLC Raises Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
How the (KALV) price action is used to our Advantage - Stock Traders Daily
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by State Street Corp - MarketBeat
State Street Corp Buys 515,179 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Is The Number One Stock Currently Moving. - Stocks Register
KALV Stock Touches 52-Week Low at $8.20 Amid Market Challenges - Investing.com Canada
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025 - Seeking Alpha
BofA Securities sets price target on Kalvista shares with Buy rating - Investing.com Australia
KalVista stock wins new Buy at BofA (KALV:NASDAQ) - Seeking Alpha
KalVista Pharmaceuticals (NASDAQ:KALV) Coverage Initiated at Bank of America - MarketBeat
Fmr LLC Increases Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista appoints new COO amid operational growth By Investing.com - Investing.com Canada
KalVista Pharmaceuticals, Inc. Appoints Jeb Ledell as Chief Operating Officer - Marketscreener.com
KalVista appoints new COO amid operational growth - Investing.com
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth - TipRanks
KalVista Pharmaceuticals appoints Jeb Ledell as COO - Seeking Alpha
KalVista Appoints Jeb Ledell as Chief Operating Officer - The Bakersfield Californian
KalVista Pharmaceuticals Taps Former AVEO Oncology Executive as New COO in Strategic Leadership Move - StockTitan
KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges - Investing.com Canada
KALV Stock Touches 52-Week Low at $8.74 Amid Market Challenges By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals (NASDAQ:KALV) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
KalVista CEO Benjamin Palleiko sells shares worth $74,363 By Investing.com - Investing.com Canada
KalVista CEO Benjamin Palleiko sells shares worth $74,363 - Investing.com
What is HC Wainwright's Forecast for KALV FY2029 Earnings? - MarketBeat
What is HC Wainwright’s Forecast for KALV FY2029 Earnings? - Defense World
KALVKalVista Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
KalVista Pharmaceuticals' (KALV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
KalVista shares hold buy rating on HAE drug outlook - Investing.com
KalVista shares hold buy rating on HAE drug outlook By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals Reports Progress in HAE Treatment - TipRanks
180,000 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Purchased by Readystate Asset Management LP - MarketBeat
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):